Engineered anti-nucleolin antibody fragment targeting cell surface necleolin on breast cancer and HCC cells selectively killed the cancer cells and reduced tumor volumes in mouse models, without injuring the normal cells [69]. This evidence concerns the gene NUCLEOLIN and hepatocellular carcinoma.